search
Back to results

Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study

Primary Purpose

Stroke, Acute, Ischemic Attack, Transient

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Sanchitongshu
placebo of Sanchitongshu
Aspirin
Clopidogrel
placebo of clopidogrel
Sponsored by
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Stroke, Acute focused on measuring Sanchitongshu, Acute Minor Stroke, Transient Ischemic Attack

Eligibility Criteria

40 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. age of 40 years to 80 years
  2. diagnosis of an acute minor ischemic stroke or transient ischemic attack; and ability to start the study drug within 24 hours after symptom onset, which was defined as the point at which the patient reported no longer being in a normal condition. Acute minor stroke was defined by a score of 3 or less at the time of randomization on the National Institutes of Health Stroke Scale(NIHSS). TIA was defined as focal brain ischemia with resolution of symptoms within 24 hours after onset plus a moderate-to-high risk of stroke recurrence(defined as a score≥4 at the time of randomization on the ABCD2). All patients were confirmed by brain CT or MRI.
  3. Patients had ability to accept the medicine and rules of the research.
  4. Patients had no serious complications and had normal renal function and liver function.

Exclusion Criteria:

  1. age younger than 40 and older than 80
  2. Patients need thrombolysis
  3. hemorrhage; other conditions, such as vascular malformation, tumor, abcess, or other major nonischemic brain disease
  4. isolated sensory symptoms(e.g., numbness), isolated visual changes, or isolated dizziness or vertigo without evidence of acute infarction on baseline CT or MRI of the head
  5. a score of more than 2 on the modified Rankin scale(scores ranges from 0(no symptoms) to 6(death))immediately before the occurrence of the index ischemic stroke or TIA, indicating moderate disability or worse at baseline
  6. TIA or minor stroke caused by angiography or surgery
  7. a clear indication for anticoagulation therapy(presumed cardiac source of embolus, such as atrial fibrillation or prosthetic cardio valve)
  8. anticipated requirement for long-term nonstudy antiplatelet drugs or for non steroidal antiinflammatory drugs affecting platelet function
  9. accompanied with severe disorders of heart, liver, and kidney
  10. severe noncardiovascular coexisting condition, with a life expectancy of less than 3 months.
  11. history of hemorrhage or bleeding tendency of other system( such as thrombocytopenic purpura)
  12. gastrointestinal bleeding or major surgery within the previous 3 months
  13. planned or probable revascularization(any angioplasty or vascular surgery)within 3 months after.Operation or Interventional Therapy require discontinuation of study drug
  14. Aspirin, clopidogrel or notoginseng allergy
  15. a history of alcoholism or drug abuse in past 12 months
  16. pregnant and lactating women, or women of childbearing age without taking any effective contraceptive measures
  17. patients have other serious disease or abnormal laboratory results that is unfavorable to join the research
  18. patients receiving other investigational drugs or devices
  19. incomprehension of the character and category of the research and unable to follow the research plan

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Sanchitongshu & placebo of lopidogrel

    placebo of Sanchitongshu & lopidogrel

    Arm Description

    sanchitongshu 1 capsule each time ,three times a day and Aspirin 75mg for 90 days ; placebo of clopidogrel 75mg daily for 21 days after randomization

    placebo of sanchitongshu1 capsule each time ,three times a day and Aspirin 75mg for 90 days;clopidogrel 75mg per day for 21 days after randomization

    Outcomes

    Primary Outcome Measures

    Percentage of patients with the180-day new vascular events, defined as any event of the following: Any stroke (ischemic or hemorrhage)

    Secondary Outcome Measures

    Percentage of patients with the 180-day new clinical vascular events (ischemic stroke/ hemorrhagic stroke/ TIA/ MI/ vascular death) as a cluster and evaluated individually
    Modified Rankin Scale score changes (continuous) and dichotomized at percentage with score 0-2 vs. 3-6 at 180 days follow-up
    Further efficacy exploratory analysis:Impairment (changes in NIHSS scores at 180 days follow-up)
    Further efficacy exploratory analysis:Impairment (changes in Barthel Index at 180 days follow-up)
    Further efficacy exploratory analysis: stroke impact scale
    Efficacy endpoint will also be analyzed stratified by etiological subtypes
    death from any cause
    Severe bleeding incidence (GUSTO definition), including fatal bleeding and symptomatic intracranial hemorrhage.
    Incidence symptomatic and asymptomatic intracranial hemorrhagic events at 180 days
    Incidence Intracranial hemorrhage events at 180 days

    Full Information

    First Posted
    November 18, 2016
    Last Updated
    November 22, 2016
    Sponsor
    Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02975076
    Brief Title
    Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study
    Official Title
    Radix/Rhizoma Notoginseng Extract (Sanchitongtshu) Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Placebo-controlled Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2016
    Overall Recruitment Status
    Unknown status
    Study Start Date
    December 2016 (undefined)
    Primary Completion Date
    November 2019 (Anticipated)
    Study Completion Date
    November 2019 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Agents of sanchi have been widely used as a complementary medicine for stroke in China. Sanchitongshu is a new Chinese patent medicine extracted from sanchi which has stronger anti-platelet activity than other agents of sanchi. The investigators's aim was to investigate the synergistic action of aspirin combined with sanchitongshu capsule in the treatment of patients with minor ischemic stroke and transient ischemic attack.
    Detailed Description
    Transient ischemic attack (TIA) and acute minor ischemic stroke are common and often lead to disabling events. In China, there are approximately 3 million new strokes every year, and approximately 30% of them are minor ischemic strokes. The incidence of TIA in China has not been determined, but on the basis of the incidence in other countries, there are probably more than 2 million TIAs annually in China. The risk of another stroke occurring after a TIA or minor stroke is high, with approximately 10 to 20% of patients having a stroke within 3 months after the index event; most of these strokes occur within the first 2 days. The role of antiplatelet therapy for secondary stroke prevention has been well established. As yet, aspirin is the only antiplatelet agent that has been studied in the acute phase of stroke, during which its benefit is modest. Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial shows that among patients with high-risk TIA or minor ischemic stroke who are initially seen within 24 hours after symptom onset, treatment with clopidogrel plus aspirin for 21 days, followed by clopidogrel alone for a total of 90 days, is superior to aspirin alone in reducing the risk of subsequent stroke events. The combination of clopidogrel with aspirin did not cause more hemorrhagic events in this patient population than aspirin alone. The analytical results provided basis for the synergistical effect of Aspirin and clopidogrel in inhibiting platelet aggregation. However, long term use of clopidogrel bring people financial burden so that the patients have less compliance of medication. Therefore, the investigators need to explore new treatment for more effective, safe and economic. Sanchi is one of the most widely used herbal medicine in China for ischemic stroke, of which panax notoginseng saponins (PNS) are the main active components. Previously there were lots of clinical trials on agents of PNS for ischemic stroke in China and had positive results. Sanchitongshu capsule is a new Chinese patent medicine extracted from sanchi. 80% of the ingredients in sanchi-tongshu capsule are panaxatriol saponins (PTS) and 60% of PTS are Rg1 which has strongest anti-platelet activity of all the PNS. PTS were proven by experiment and phase III clinical trials to have antithrombosis effect through mechanisms of inhibiting platelet aggregation, decreasing blood viscosity, strengthening activities of fibrinolysis system, and promoting vascular endothelial NO releasing. More recent experimental studies indicated anti-inflammatory and neuroprotective effect of PTS. Compared with other agents of Sanchi, Sanchitongshu capsule contains higher purity of PTS and Rg1. Thus, Sanchitongshu capsule theoretically should be vigorous in improving ischemic status after ischemic stroke. Include, the investigators will investigate the synergistic action of aspirin combined with sanchitongshu capsule in the treatment of patients with minor ischemic stroke and transient ischemic attack.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Stroke, Acute, Ischemic Attack, Transient
    Keywords
    Sanchitongshu, Acute Minor Stroke, Transient Ischemic Attack

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    InvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    120 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Sanchitongshu & placebo of lopidogrel
    Arm Type
    Experimental
    Arm Description
    sanchitongshu 1 capsule each time ,three times a day and Aspirin 75mg for 90 days ; placebo of clopidogrel 75mg daily for 21 days after randomization
    Arm Title
    placebo of Sanchitongshu & lopidogrel
    Arm Type
    Placebo Comparator
    Arm Description
    placebo of sanchitongshu1 capsule each time ,three times a day and Aspirin 75mg for 90 days;clopidogrel 75mg per day for 21 days after randomization
    Intervention Type
    Drug
    Intervention Name(s)
    Sanchitongshu
    Other Intervention Name(s)
    Radix/Rhizoma Notoginseng extract
    Intervention Description
    The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.
    Intervention Type
    Drug
    Intervention Name(s)
    placebo of Sanchitongshu
    Intervention Description
    The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).
    Intervention Type
    Drug
    Intervention Name(s)
    Aspirin
    Other Intervention Name(s)
    Aspirin Enteric-coated Tablets
    Intervention Type
    Drug
    Intervention Name(s)
    Clopidogrel
    Other Intervention Name(s)
    Clopidogrel Bisulfate
    Intervention Type
    Drug
    Intervention Name(s)
    placebo of clopidogrel
    Primary Outcome Measure Information:
    Title
    Percentage of patients with the180-day new vascular events, defined as any event of the following: Any stroke (ischemic or hemorrhage)
    Time Frame
    180 days
    Secondary Outcome Measure Information:
    Title
    Percentage of patients with the 180-day new clinical vascular events (ischemic stroke/ hemorrhagic stroke/ TIA/ MI/ vascular death) as a cluster and evaluated individually
    Time Frame
    180 days
    Title
    Modified Rankin Scale score changes (continuous) and dichotomized at percentage with score 0-2 vs. 3-6 at 180 days follow-up
    Time Frame
    180 days
    Title
    Further efficacy exploratory analysis:Impairment (changes in NIHSS scores at 180 days follow-up)
    Time Frame
    180 days
    Title
    Further efficacy exploratory analysis:Impairment (changes in Barthel Index at 180 days follow-up)
    Time Frame
    180 days
    Title
    Further efficacy exploratory analysis: stroke impact scale
    Time Frame
    180 days
    Title
    Efficacy endpoint will also be analyzed stratified by etiological subtypes
    Time Frame
    180 days
    Title
    death from any cause
    Time Frame
    180 days
    Title
    Severe bleeding incidence (GUSTO definition), including fatal bleeding and symptomatic intracranial hemorrhage.
    Time Frame
    180 days
    Title
    Incidence symptomatic and asymptomatic intracranial hemorrhagic events at 180 days
    Time Frame
    180 days
    Title
    Incidence Intracranial hemorrhage events at 180 days
    Time Frame
    180 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    40 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: age of 40 years to 80 years diagnosis of an acute minor ischemic stroke or transient ischemic attack; and ability to start the study drug within 24 hours after symptom onset, which was defined as the point at which the patient reported no longer being in a normal condition. Acute minor stroke was defined by a score of 3 or less at the time of randomization on the National Institutes of Health Stroke Scale(NIHSS). TIA was defined as focal brain ischemia with resolution of symptoms within 24 hours after onset plus a moderate-to-high risk of stroke recurrence(defined as a score≥4 at the time of randomization on the ABCD2). All patients were confirmed by brain CT or MRI. Patients had ability to accept the medicine and rules of the research. Patients had no serious complications and had normal renal function and liver function. Exclusion Criteria: age younger than 40 and older than 80 Patients need thrombolysis hemorrhage; other conditions, such as vascular malformation, tumor, abcess, or other major nonischemic brain disease isolated sensory symptoms(e.g., numbness), isolated visual changes, or isolated dizziness or vertigo without evidence of acute infarction on baseline CT or MRI of the head a score of more than 2 on the modified Rankin scale(scores ranges from 0(no symptoms) to 6(death))immediately before the occurrence of the index ischemic stroke or TIA, indicating moderate disability or worse at baseline TIA or minor stroke caused by angiography or surgery a clear indication for anticoagulation therapy(presumed cardiac source of embolus, such as atrial fibrillation or prosthetic cardio valve) anticipated requirement for long-term nonstudy antiplatelet drugs or for non steroidal antiinflammatory drugs affecting platelet function accompanied with severe disorders of heart, liver, and kidney severe noncardiovascular coexisting condition, with a life expectancy of less than 3 months. history of hemorrhage or bleeding tendency of other system( such as thrombocytopenic purpura) gastrointestinal bleeding or major surgery within the previous 3 months planned or probable revascularization(any angioplasty or vascular surgery)within 3 months after.Operation or Interventional Therapy require discontinuation of study drug Aspirin, clopidogrel or notoginseng allergy a history of alcoholism or drug abuse in past 12 months pregnant and lactating women, or women of childbearing age without taking any effective contraceptive measures patients have other serious disease or abnormal laboratory results that is unfavorable to join the research patients receiving other investigational drugs or devices incomprehension of the character and category of the research and unable to follow the research plan
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Xiaorong Wang, Master
    Phone
    13621712767
    Email
    wangxr_mail@163.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Fei Lu
    Phone
    021-25076146
    Email
    xinhuakeyan@163.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Xinhua Hospital
    Organizational Affiliation
    Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes

    Learn more about this trial

    Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study

    We'll reach out to this number within 24 hrs